 












B. Lynne Parshall, Ionis Pharmaceuticals, Inc. Chief Operating Officer - REDBOOKS








































Brands, Marketers, Agencies. Search Less. Sell More.





/   SIGN IN

GET A FREE TRIAL   
CONTACT US: (800) 908-5395





















B. Lynne Parshall
Chief Operating Officer, Ionis Pharmaceuticals, Inc.

EMAIL: 
                      







              Real-time sales trigger feed - generated by REDBOOKS machine learning and natural language processing technology, tracking 800,000+ news sources to aggregate all new executives, job/role changes and news on decision makers, brands and agencies in the media/marketing industry.
              

              This sales feed is for B. Lynne Parshall at Ionis Pharmaceuticals, Inc.. B. Lynne Parshall works as Chief Operating Officer , acting in a Executive Management role .  Ionis Pharmaceuticals, Inc. is a leader in Pharmaceuticals & Health Care Products .
              REDBOOKS tracks personnel changes for advertisers spending over $1 million annually.
              

              For more Executive Management leads or media/marketing prospecting automation, start a free trial now.
              

Recent Related News


06/19/2017:


Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISISAR Rx to Treat Prostate Cancer

..... AR is a well-validated target in prostate cancer, and our antisense approach may allow us to avoid the limitations of other therapeutic approaches that others have tried to inhibit this target," said B. Lynne Parshall, chief operating officer at Isis. "AstraZeneca's extensive experience in successfully developing and commercializing drugs to treat hormone-related cancers, like prostate cancer, is a significant advantage for program success. .....

People In This Article:
B. Lynne Parshall
,                                            Brett Monia
 

05/31/2017:


IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Submission of Matters to a Vote of Security Holders

..... Berthelsen
84,173,655
9,020,996
21,105,539
B. Lynne Parshall
87,494,494
5,700,157
21,105,539
Joseph H. Wender
84,148,943
9,045,708
21,105,539
The Companys stockholders elected the foregoing candidates, by
affirmative votes by a majority of the votes of the shares.
.....

People In This Article:
B. Lynne Parshall
 






Learn more about B. Lynne Parshall  and 260,000+ key contacts

  Create targeted lead lists

  Gain insider knowledge with advanced machine  learning
  Real-time verified contact info



Enter Work Email:

Please enter email address.
 Please enter valid email address.









             Learn more about B. Lynne Parshall and 260,000+ key contacts
            



























First Name *

 Please enter first name.




Last Name *

 Please enter last name.






Company Name *

 Please enter company name.






Email *





Phone *

 Please enter phone number.
 Please enter 10 digits number.





What industry are you in? *  
                (Please select one the categories below)
Please enter value for the industry.




                     Media Sales
                  




                     Production
                  




                     Ad-Tech/Mar-Tech
                  




                     Sponsorship Sales
                  



  Agency New Business
                  



  Other:
                  




What is your role? *
                 
                 (Please select one the categories below)
Please enter value for the role.



  C-Suite
                  



  VP/Manager
                  



  Sales Rep
                  



  Other:
                  














Thank you for registering for a Free REDBOOKS.com Trial!
We are processing your request and will be in touch shortly to get you started!
For Immediate Assistance, please call us at (800) 908-5395 or email us at info@redbooks.com


























Home
Learn More
FREE Trial


Features




AD THINK Events
Thought Leadership Events
Top Advertiser Directory
Top Agency Directory



Add Your Agency
Update Your Agency
Agency Showcase
Advertising Associations
Creative Spotlight
Services and Suppliers


About Us
Blog
Contact Us
Jobs
Terms & Conditions
Privacy Policy





Customer Support
(800) 908-5395
Connect with us




















Copyright © 2017 Red Books LLC. All rights reserved






































Parshall, B. Lynne - The Wall Street Transcript













































 





































B. Lynne Parshall
B. LYNNE PARSHALL is Director, Executive Vice President and Chief
Financial Officer of Isis Pharmaceuticals. She is responsible for
overseeing the operations of development chemistry, manufacturing and
pharmaceutics, finance, legal, patent affairs and is also very involved
in the company’s investor relations and business development activities.
Ms. Parshall has been with Isis for 13 years. Previously, Ms. Parshall
was a Partner with the firm of Cooley Godward LLP where she represented
several health care companies in a general practice specializing in
corporate partnering and other technology-based transactions. Ms.
Parshall received her JD at Stanford Law School, Stanford, California,
and her BA from Harvard University, Cambridge, Massachusetts. Ms.
Parshall is currently a member of the Board of Trustees of The Bishop’s
School and the Surf Soccer Board of Directors. She is also a member of
the Licensing Executives Society and a member of the American,
Californian, and San Diego bar associations.
Related Interviews:B.lynne Parshall - Isis Pharmaceuticals Inc (isis)October 26, 2004







CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google












 






Lynne B. Parshall, Chief Executive Officer and Chief Operating Officer, Ionis Pharmaceuticals


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Lynne B. Parshall



Chief Executive Officer and Chief Operating Officer
at
Ionis Pharmaceuticals


Location: 





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Lynne B. Parshall



Chief Executive Officer and Chief Operating Officer
at
Ionis Pharmaceuticals


Location: 




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Ms. Parshall is Director and Chief Operating Officer of Isis Pharmaceuticals. She is responsible for overseeing the operations of finance, legal, patents, manufacturing, information technology, regulatory and alliance management, health and safety, facilities, corporate communications, and business and corporate development. Ms. Parshall joined Isis in November 1991.
Previously, Ms. Parshall was a Partner with the firm of Cooley Godward LLP, now Cooley LLP, where she represented several health care companies in a general practice specializing in corporate partnering and other technology-based transactions.
Ms. Parshall received her J.D. at Stanford Law School, Stanford, California and her B.A. from Harvard University, Cambridge, Massachusetts. Ms. Parshall is currently on the Board of Regulus Therapeutics Inc., a company co-founded by Isis, and Cytokinetics, Inc. Ms. Parshall is also a member of the Licensing Executives Society and a member of the American, California, and San Diego bar associations.



2

Companies in Career





N/A

Related Markets





1

Colleagues





N/A

Related Investments








Alias
N/A



Industry
R&D in Biotech, Environmental and various industries (no marketing product yet)




Tags
Biotechnology




Topics of Influence












N/A







N/A



























Careers








Achievements








Investments








Related People






 Edit
View all 



Lynne B. ParshallCareer (2)






Nov-1991




Ionis Pharmaceuticals



Chief Executive Officer and Chief Operating Officer







1980 to 1991




Cooley LLP



Partner








Competencies










 Edit
View all 



Lynne B. ParshallEducation (2)










Stanford University













Harvard University












 Edit



Lynne B. ParshallAchievements and Recognitions





Add Milestone


No milestones has been recorded for Lynne B. Parshall






 Edit



Lynne B. ParshallLinks





Add Link


No links has been recorded for Lynne B. Parshall









Lynne B. ParshallInvestments/Acquisitions





No investments has been recorded for Lynne B. Parshall









Lynne B. ParshallInvestments Representing Others





No investment reps has been recorded for Lynne B. Parshall








Lynne B. ParshallRelated People








Colleagues at Ionis Pharmaceuticals







Stanley T. Crooke

Founder, Chairman and Chief Executive Officer













View all 



Lynne B. ParshallRecommended Market Profiles (8)








Telemedicine

10,000 or More employees
19 companies








Social Media Marketing (ChiefMartec.com)

5,000 - 10,000 employees
111 companies








Big Data Universe List of Lists

10,000 or More employees
533 companies








Aggregated Marketing Technology

10,000 or More employees
2650 companies








Shared Economy Landscape (Jeremiah Owyang)

10,000 or More employees
267 companies








Inside Sales Landscape

10,000 or More employees
650 companies
























B. Lynne Parshall, Esq. - Ionis Pharmaceuticals



























































































B. Lynne Parshall, Esq.




Director & Chief Operating Officer
Ms. Parshall is Director and Chief Operating Officer of Ionis Pharmaceuticals. She is responsible for overseeing the operations of finance, legal, patents, manufacturing, information technology, regulatory and alliance management, health and safety, facilities, corporate communications, and business and corporate development. Ms. Parshall joined Ionis in November 1991.
Previously, Ms. Parshall was a Partner with the firm of Cooley Godward LLP, now Cooley LLP, where she represented several health care companies in a general practice specializing in corporate partnering and other technology-based transactions.
Ms. Parshall received her J.D. at Stanford Law School, Stanford, California and her B.A. from Harvard University, Cambridge, Massachusetts. Ms. Parshall is currently on the Board of Cytokinetics, Inc. Ms. Parshall is also a member of the Licensing Executives Society and a member of the American, California, and San Diego bar associations.






















About

Mission & Values
In The Community
Management
Board of Directors
Contact


Patients

Patient Resources
Clinical Trials

Drug Approval Process
Learn More About Ionis’ Clinical Trials




Pipeline
R&D

Antisense Technology

Discovery Platform
Basic Science
Antisense Drugs
Medicinal Chemistry
Antisense Approaches


Intellectual Property
Strategic Alliances

Pharmaceutical Partners
Satellite Companies




Investors & Media

News & Events

Press Releases
Archived Webcasts
Event Calendar


Corporate Governance

Board of Directors
Board Criteria
Director Compensation and Board Meeting Attendance
Committee Composition
Certificates of Incorporation
Bylaws
Code of Ethics
Clawback Policy
RSU Holding Guidelines
Annual Meeting


Stock Information

Stock Quote
Stock Chart
Analyst Coverage
Ownership Profile


Financials

Annual Reports
SEC Filings


Shareholder Services

Investor FAQ
Information Request


Press Kit


Careers

Available Positions

Search Open Jobs
Browse Open Jobs
Edit Your Profile
View Submitted Applications


Culture & Values
Benefits
Equal Opportunity
Intern Program
Post-Doctoral Program
















 





COO of Ionis Pharmaceuticals (NASDAQ:IONS), Parshall B Lynne, sells 4,625 shares worth 7,828








































Stay Connected

Latest Posts in RSS

BusinessEntertainmentFeatured NewsFeatured Press ReleaseFinanceHealthLifestyleNationNon FirstPageOriginalPress ReleaseReviewShoppingSportsStocksTechnologyTravelWorld


Latest Comments in RSS


 / 













EmpoweredNews
World News Summary Helping You Stay Informed









Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping




Our Writers
About Us
Privacy Policy
Contact Us
Advertise
Press Releases
















COO of Ionis Pharmaceuticals (NASDAQ:IONS), Parshall B Lynne, sells 4,625 shares worth $227,828
According to Ionis Pharmaceuticals's most recent Form 4 filing with the SEC dated Mar 02 07:12 PM, company COO, Parshall B Lynne disclosed selling 4,625 shares at a cost of $49.26. At the time of this transaction (Mar 01), this trade was worth $227,828 in total. As of Mar 01, Parshall B Lynne now owns 25,651 shares in total worth about $1,373,867.56. 
For the last few recent trades made by Ionis Pharmaceuticals (NASDAQ:IONS) COO, Parshall B Lynne, we have the following information:




SEC Form 4 filing: Jan 17: Sold 7,246 shares at the rate of $46.29 per share. Total worth of this trade was $335,414. Total number of shares owned as of Jan 17 were 18,494
SEC Form 4 filing: Dec 15: Sold 4,000 shares at the rate of $50.00 per share. Total worth of this trade was $200,000. Total number of shares owned as of Dec 15 were 0
SEC Form 4 filing: Dec 01: Sold 12,500 shares at the rate of $42.23 per share. Total worth of this trade was $527,865. Total number of shares owned as of Dec 01 were 16,693




					Posted by  



George Daniels 

					
					on Thursday March 02 2017, 7:45 PM EDT. 

All trademarks acknowledged. 
Filed under Stocks.

	Comments and Trackbacks closed.	
 Follow responses: 
RSS 2.0




Comments are closed


 Latest News 
EVP, CL&AO of Vertex Pharmaceuticals Incorpor (NASDAQ:VRTX), Parini Michael, sells 10,829 shares worth $1,743,469
CEO & President of Vertex Pharmaceuticals Incorpor (NASDAQ:VRTX), Leiden Jeffrey M, sells 184,374 shares worth $29,684,214
EVP GMDA, CMO of Vertex Pharmaceuticals Incorpor (NASDAQ:VRTX), Chodakewitz Jeffrey, sells 39,833 shares worth $6,413,113
EVP, Global Research and CSO of Vertex Pharmaceuticals Incorpor (NASDAQ:VRTX), Altshuler David, sells 28,979 shares worth $4,665,619
EVP\Chief Commercial Officer of Vertex Pharmaceuticals Incorpor (NASDAQ:VRTX), Arbuckle Stuart A, sells 89,400 shares worth $14,441,830
See Remarks of Aimmune Therapeutics (NASDAQ:AIMT), Sheehy Douglas T., sells 7,460 shares worth $161,558
SVP and General Counsel of NxStage Medical (NASDAQ:NXTM), Swan Winifred L, sells 3,500 shares worth $84,560
Chief Product Officer of Facebook (NASDAQ:FB), Cox Christopher K, sells 16,000 shares worth $2,628,483
Founder & Executive Chairman of Ellie Mae (NYSE:ELLI), Anderman Sigmund, sells 1,319 shares worth $144,958
Chief Financial Officer of Civitas Solutions (NYSE:CIVI), Holler Denis M., sells 5,300 shares worth $101,230

 


News Categories 
Business (7)

Stocks (15,791)



Entertainment (1,297)

Featured News (3,487)

Featured Press Release (254,563)

Finance (309)

Health (653)

Lifestyle (19)

Nation (90)

Non FirstPage (2)

Original (47)

Press Release (18)

Review (1)

Shopping (267)

Sports (613)

Technology (195)

Travel (286)

World (1,368)


  Featured Press Releases 
2017 to 2022 Asia-Pacific Shutoff Valve Market Research Analysis Report
2017 to 2022 Asia-Pacific Rodenticide Market Research Analysis Report
Rubber Tapes 2017 Global Sales Market Report including key players Achem & 3M
Rubber Coatings 2017 Global Sales Market Report including key players Pro Guard & Cantech Canada
Rigid Intermediate Bulk Container (RIBC) 2017 Global Sales Market Report including key players Greif, Inc. & Mondi Group
Rapid Prototyping Machines 2017 Global Sales Market Report including key players DATRON & Roland DGA
Reverse Vending Machine 2017 Global Sales Market Report including key players Tomra Systems ASA & Wincor-Nixdorf
2017 to 2022 Asia-Pacific Printer Toner Cartridge Market Research Analysis Report
Radiation Shielding Glass 2017 Global Sales Market Report including key players Electric Glass Building Materials & Raybloc
Quantum Computing 2017 Global Sales Market Report including key players Microsoft & Intel







Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping
 

About Us
Contact Us
Privacy Policy
Advertise
Press Releases
Terms Of Service
 
Log in 














B Parshall, Ionis Pharmaceuticals Inc: Profile & Biography - Bloomberg


































































  


























Feedback





B Parshall

Chief Operating Officer,
Ionis Pharmaceuticals Inc






Career History




Chief Operating Officer
Ionis Pharmaceuticals Inc, 12/2015-PRESENT


Chief Operating Officer
Isis Pharmaceuticals Inc, 1/2015-12/2015


COO/Secretary
Isis Pharmaceuticals Inc, 1/2013-1/2015


CFO/COO/Secretary
Isis Pharmaceuticals Inc, UNKNOWN-12/2013


Exec VP/CFO/COO/Secy
Isis Pharmaceuticals Inc, 12/2007-1/2008


Exec VP/CFO/Secretary
Isis Pharmaceuticals Inc, 12/1995-12/2007


Senior VP/CFO/Secretary
Isis Pharmaceuticals Inc, 6/1994-12/1995


Senior VP/Secretary
Isis Pharmaceuticals Inc, 2/1993-6/1994


VP/Secretary
Isis Pharmaceuticals Inc, 11/1991-2/1993


Partner
Cooley Godward LLP, 1986-1991



Isis Pharmaceuticals Inc, 1991-11/1991


VP:Business Devlopment
Biotrack Inc, 1988-1989


Exec VP/CFO/COO
Isis Pharmaceuticals Inc, 1/2008-UNKNOWN


Show More









Website:
www.ionispharma.com






Corporate Information
Address:

2855 Gazelle Court
Carlsbad, CA 92010
United States


Phone:
1-760-931-9200


Fax:
1-619-931-9639


Web url:
www.ionispharma.com











From The Web












Personal Information



Education



Stanford Law School
JD, 1979


President & Fellows of Harvard College
Master's Degree, 1976


Harvard College
Bachelor's Degree


Show More








Awards & Publications



Certificates




Bar Admitted









Memberships



Board Memberships




Ionis Pharmaceuticals Inc


Board Member, 12/2015-PRESENT




Akcea Therapeutics Inc


Board Member, 1/2015-PRESENT




Cytokinetics Inc


Board Member, 2/2013-PRESENT




Isis Pharmaceuticals Inc


Board Member, 9/2000-12/2015




Regulus Therapeutics Inc


Board Member, 1/2009-6/2015




Cardiodynamics International Corp


Board Member, 7/2005-8/2009




Corautus Genetics Inc


Board Member, UNKNOWN-6/2007



Show More





Other Memberships




California Bar Assn


Member




San Diego Bar Assn


Member




American Bar Assn


Member




Bishop's Schl


Trustee




 Licensing Executives Society 


Member



Show More








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data

































   B. Parshall | Isis Pharmaceuticals , Inc. | ZoomInfo.com